An Indirect Treatment Comparison of the Cardiovascular Protective Effect of Semaglutide vs. Liraglutide in Subjects with Type 2 Diabetes

被引：0
|
作者：
Chubb, Barrie
Bog, Martin
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-790-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
790-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk
    Sanyal, Arun J.
    Hansen, Morten
    Linder, Martin
    Newsome, Philip N.
    [J]. HEPATOLOGY, 2017, 66 : 1175A - 1175A
  • [2] Cardiovascular safety of liraglutide for the treatment of type 2 diabetes
    Chudleigh, R. A.
    Bain, Steve
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (05) : 627 - 635
  • [3] Tirzepatide 5, 10, and 15 mg vs Injectable Semaglutide 0.5 mg for the Treatment of Type 2 Diabetes-An Indirect Treatment Comparison
    Pantalone, Kevin M.
    Tofe, Santiago
    Fan, Ludi
    Paik, Jim S.
    Ranta, Kari T.
    Sapin, Helene
    Osumili, Beatrice
    [J]. DIABETES, 2023, 72
  • [4] Liraglutide and Semaglutide Reduce Cardiovascular Events in Patients With Type 2 Diabetes and Peripheral Arterial Disease
    Verma, Subodh
    Rasmussen, Soren
    Saevereid, Hans Askelund
    Ripa, Maria Sejersten
    [J]. CIRCULATION, 2019, 140
  • [5] Liraglutide and semaglutide reduce cardiovascular events in patients with type 2 diabetes and peripheral arterial disease
    Verma, S.
    Rasmussen, S.
    Saevereid, H. A.
    Ripa, M. Sejersten
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S283 - S284
  • [6] Effect of liraglutide vs empagliflozin treatment on cardiovascular biomarkers in type 2 diabetic patients
    Baldassarre, M. P. A.
    Coluzzi, S.
    Tinari, C.
    Febo, F.
    Lanuti, P.
    Ercolino, E.
    Formoso, G.
    Consoli, A.
    [J]. DIABETOLOGIA, 2019, 62 : S559 - S559
  • [7] Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
    Doggrell, Sheila A.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (05) : 489 - 492
  • [8] Effect of Liraglutide on Cardiovascular Markers in Type 2 Diabetes Mellitus
    Ren, Wei
    Guo, Jianjin
    Liu, Jie
    Xi, Guangxia
    [J]. DIABETES, 2015, 64 : A339 - A339
  • [9] Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Chang, Denise
    Aroda, Vanita R.
    [J]. DIABETES, 2016, 65 : A49 - A49
  • [10] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Marso, Steven P.
    Daniels, Gilbert H.
    Brown-Frandsen, Kirstine
    Kristensen, Peter
    Mann, Johannes F. E.
    Nauck, Michael A.
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Ravn, Lasse S.
    Steinberg, William M.
    Stockner, Mette
    Zinman, Bernard
    Bergenstal, Richard M.
    Buse, John B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 311 - 322
12345